Inovio Pharmaceuticals (INO) Receives a Buy from Piper Sandler
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $5.00. The company’s shares closed yesterday at $1.49.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tenthoff covers the Healthcare sector, focusing on stocks such as iTeos Therapeutics, Inovio Pharmaceuticals, and Arrowhead Pharmaceuticals. According to TipRanks, Tenthoff has an average return of -17.0% and a 27.98% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inovio Pharmaceuticals with a $6.90 average price target.
INO market cap is currently $75.93M and has a P/E ratio of -0.47.
Read More on INO:
Disclaimer & DisclosureReport an Issue
- Inovio Pharmaceuticals Reports Q2 2025 Financial Progress
- Inovio reports Q2 EPS (61c), consensus (62c)
- Options Volatility and Implied Earnings Moves Today, August 12, 2025
- Inovio announces peer-reviewed data from INO-3107 study
- Options Volatility and Implied Earnings Moves This Week, August 11 – August 14, 2025
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.